aibio
Listings ·
Liminatus Pharma regains Nasdaq compliance after 1-for-50 reverse split
Nasdaq told the company on September 24, 2026 that its shares had closed above $1.00 for 13 straight trading days, closing the matter.
LIMN Liminatus Pharma, Inc.
Liminatus Pharma (LIMN) news LIMN reverse split and Nasdaq notice news
Latest Liminatus Pharma news
- Listings
Liminatus Pharma sets 1-for-50 reverse stock split to meet Nasdaq minimum bid price requirement
Liminatus will cut its shares 50 to 1 at the close of trading on August 20, 2026. The Nasdaq Panel now requires a $1.00 closing bid for ten consecutive trading days by September 3, after notices on market value and bid price.
- Listings
Liminatus Pharma gets Nasdaq deficiency notice over late Form 10-Q
Liminatus Pharma (Nasdaq: LIMN) has until October 21, 2025 to submit a plan to regain compliance after the delayed filing of its report for the period ended June 30, 2025. The stock keeps trading for now.
- Distress
Liminatus Pharma files late notice for quarterly report for June 30, 2025
The company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace period.
What Liminatus Pharma does
Liminatus Pharma, Inc. describes itself as a pre-clinical stage, single-asset biopharmaceutical company developing cancer therapies that use the body immune system. It refers to its operating history through Liminatus Pharma, LLC, which became part of the company through a business combination with Iris Acquisition Corp. Its clinical candidate is a humanized anti-CD47 monoclonal antibody, a next generation CD47 checkpoint inhibitor with the code name IBA101. The initial indication expected for IBA101 is patients with advanced solid cancers, including non-small cell lung cancer. The text explains that CD47 acts as a do not eat me signal that lets cancer cells avoid immune detection, and that CD47 blockade promotes uptake of tumor cells by macrophages. It says first generation CD47 agents caused anemia and thrombocytopenia because they bound red blood cells and platelets. The company states that its next generation antibody preferentially binds immune cells and does not bind red blood cells and platelets in the same way.
| Product or program | What it is | Stage |
|---|---|---|
| IBA101 | Next generation humanized anti-CD47 checkpoint inhibitor for advanced solid cancers | Pre-clinical stage company; described as clinical candidate |
Liminatus Pharma annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.7 million | |
| Net income (loss) | -$10.2 million | -$3.5 million |
| Cash from operations | -$10.0 million | -$1.5 million |
| Cash and equivalents | $0 |
Questions about Liminatus Pharma
Did Liminatus Pharma do a reverse stock split?
Our latest story on this, dated Sep 29, 2026: "Liminatus Pharma regains Nasdaq compliance after 1-for-50 reverse split". The story links the filing or release it is based on. Read the story.
Has Liminatus Pharma received a Nasdaq deficiency notice?
Our latest story on this, dated Aug 25, 2025: "Liminatus Pharma gets Nasdaq deficiency notice over late Form 10-Q". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Liminatus Pharma?
Liminatus Pharma, Inc. trades under the ticker LIMN on NASDAQ.
Where is Liminatus Pharma listed?
Liminatus Pharma, Inc. is listed on NASDAQ.
What is the SEC CIK of Liminatus Pharma?
The SEC Central Index Key (CIK) for Liminatus Pharma, Inc. is 1971387. Its filings are on SEC EDGAR.
How many shares does Liminatus Pharma have outstanding?
67,160,362 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Liminatus Pharma listed under?
Our directory records Liminatus Pharma, Inc. under United States.
What does Liminatus Pharma do?
Our directory classifies Liminatus Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Liminatus Pharma?
The ISIN recorded for Liminatus Pharma, Inc. is US53271X2071.
Does aibio.space cover Liminatus Pharma?
aibio.space lists Liminatus Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Liminatus Pharma incorporated?
SEC records list its state or country of incorporation as DE.
What does Liminatus Pharma develop?
Liminatus Pharma, Inc. describes itself as a pre-clinical stage, single-asset biopharmaceutical company developing cancer therapies that use the body immune system. It refers to its operating history through Liminatus Pharma, LLC, which became part of the company through a business combination with Iris Acquisition Corp. Its clinical candidate is a humanized anti-CD47 monoclonal antibody, a next generation CD47 checkpoint inhibitor with the code name IBA101.
What is IBA101 from Liminatus Pharma?
IBA101: Next generation humanized anti-CD47 checkpoint inhibitor for advanced solid cancers Stage: Pre-clinical stage company; described as clinical candidate.
Is Liminatus Pharma profitable?
Liminatus Pharma, Inc. reported a net loss of $10.2 million for the fiscal year ended Dec 31, 2025, and used $10.0 million of cash in operations, per its annual report to the SEC.
How much cash does Liminatus Pharma have?
$0 in cash at Mar 31, 2025, per its 10-Q.
Investor discussion: Liminatus Pharma
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,7.01,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). Source
- Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Liminatus Pharma, Inc.
- CIK
- 1971387
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- LIMN (Nasdaq), LIMNW (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
- Phone
- 213-273-5453
- Shares outstanding
- 67,160,362 as of 2026-08-14 (10-Q filed 2026-08-14)
- Former names
- Iris Parent Holding Corp.
Recent filings
Listing details
- Company
- Liminatus Pharma, Inc.
- Ticker
- LIMN
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US53271X2071
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction